celz_10k.htm

XML 35 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2020	Mar. 12, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		1,136,457,773
Entity Public Float			$ 1,139,011
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

XML 36 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 98,012	$ 88,648
Accounts receivable	0	5,600
Total Current Assets	98,012	94,248
OTHER ASSETS
Licenses, net of amortization	619,763	436,555
TOTAL ASSETS	717,775	530,803
CURRENT LIABILITIES
Accounts payable	350,899	320,785
Accrued expenses	159,771	120,492
Management fee and patent liabilities - related parties	468,782	240,082
Convertible notes payable, net of discount of $409,649 and $560,899, respectively	788,701	1,062,266
Advances from related party	10,800	10,800
Derivative liabilities	38,741,832	6,847,877
Total Current Liabilities	40,520,785	8,602,302
TOTAL LIABILITIES	40,520,785	8,602,302
Commitments and contingencies	0	0
STOCKHOLDERS' DEFICIT
Preferred Stock Value	0	0
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 768,540,617 and 22,493,046 issued and 768,536,617 and 22,489,046 outstanding at December 31, 2020 and 2019, respectively	768,536	22,489
Additional paid-in capital	21,315,690	17,468,018
Accumulated deficit	(61,890,236)	(25,565,006)
TOTAL STOCKHOLDERS' DEFICIT	(39,803,010)	(8,071,499)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	717,775	530,803
Preferred Stock Series A [Member]
STOCKHOLDERS' DEFICIT
Preferred Stock Value	$ 3,000	$ 3,000

XML 37 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt discount, convertible notes payable	$ 409,649	$ 560,899
LIABILITIES AND STOCKHOLDERS' DEFICIT
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	768,540,617	22,493,046
Common stock, shares outstanding	768,536,617	22,489,046
Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS' DEFICIT
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	7,000,000	7,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred Class A [Member]
LIABILITIES AND STOCKHOLDERS' DEFICIT
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	3,000,000	3,000,000
Preferred stock, shares outstanding	3,000,000	3,000,000

XML 38 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED STATEMENT OF OPERATIONS
Revenues	$ 164,500	$ 165,500
Cost of revenues	50,596	45,499
Gross profit	113,904	120,001
OPERATING EXPENSES
Selling, general and administrative	1,161,947	1,223,219
Amortization of patent costs	66,792	26,950
TOTAL EXPENSES	1,228,739	1,250,169
Operating loss	(1,114,835)	(1,130,168)
OTHER INCOME/(EXPENSE)
Interest expense	(1,229,590)	(1,895,528)
Gain loss on extinguishment of convertible notes	0	(366,042)
Change in fair value of derivatives liabilities	(33,980,805)	(5,091,935)
Total other income (expense)	(35,210,395)	(7,353,505)
LOSS BEFORE PROVISION FOR INCOME TAXES	(36,325,230)	(8,483,673)
Provision for income taxes	0	0
NET LOSS	$ (36,325,230)	$ (8,483,673)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.13)	$ (0.82)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	289,730,374	10,343,162

XML 39 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (36,325,230)	$ (8,483,673)
Adjustments to reconcile net loss to net cash from operating activities:
Stock-based compensation	170,323	0
Amortization	66,792	26,950
Amortization of debt discounts	979,960	1,723,451
Change in fair value of derivatives liabilities	33,980,805	5,091,935
Loss on extinguishment of convertible notes payable	0	266,042
Excess consideration issued in connection with relieve of management fees and patent liability	0	100,000
Changes in assets and liabilities:
Accounts receivable	5,600	4,000
Accounts payable	30,114	(11,054)
Accrued expenses	167,029	189,256
Management fee payable	490,051	(120,000)
Net cash used in operating activities	(434,556)	(1,213,093)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities	(250,000)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable to related party	0	(50,000)
Proceeds from notes payable to related party	0	50,000
Payments on convertible notes payable	(17,000)	(263,411)
Prepayment premiums paid on convertible notes payable	0	(41,699)
Proceeds from convertible notes payable	710,920	1,302,795
Net cash provided from financing activities	693,920	997,685
NET INCREASE (DECREASE) IN CASH	9,364	(215,408)
BEGINNING CASH BALANCE	88,648	304,056
ENDING CASH BALANCE	98,012	88,648
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	6,000	18,177
Cash payments for income taxes	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Related party liability incurred for additional patent costs	0	300,000
Beneficial conversion feature issued with Allogenics patent liability	101,351	0
Conversion of notes payable, accrued interest and derivative liabilities into common stock	4,162,045	4,156,811
Conversion of management fees and patent liability into common stock	$ 160,000	$ 138,000

XML 40 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Series A Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2018		3,000,000	6,018,075
Balance, amount at Dec. 31, 2018	$ (3,994,637)	$ 3,000	$ 6,018	$ 13,077,678	$ (17,081,333)
Common stock issued for cashless warrant exercise, shares	531,247		531,247
Common stock issued for cashless warrant exercise, amount	$ 0	$ 0	$ 531	(531)	0
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares			11,873,057
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,501,275	$ 0	$ 11,873	1,489,402	0
Common stock issued for related party management fee and patent liabilities, shares			4,066,667
Common stock issued for related party management fee and patent liabilities, amount	250,000	$ 0	$ 4,067	245,933	0
Relief of derivative liabilities	2,655,536	0	0	2,655,536	0
Net loss	(8,483,673)	$ 0	$ 0	0	(8,483,673)
Beneficial conversion feature issued with Allogenics patent liability	0
Balance, shares at Dec. 31, 2019		3,000,000	22,489,046
Balance, amount at Dec. 31, 2019	(8,071,499)	$ 3,000	$ 22,489	17,468,018	(25,565,006)
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares			681,731,395
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, amount	1,366,705	$ 0	$ 681,731	684,974	0
Common stock issued for related party management fee and patent liabilities, shares			64,314,883
Common stock issued for related party management fee and patent liabilities, amount	160,000	$ 0	$ 64,315	95,685	0
Relief of derivative liabilities	2,795,340	0	0	2,795,340	0
Net loss	(36,325,230)	0	0	0	(36,325,230)
Beneficial conversion feature issued with Allogenics patent liability	101,351		0	101,351	0
Stock-based compensation	170,323	$ 0	$ 0	170,323	0
Differences in shares from reverse stock split, shares			1,293
Differences in shares from reverse stock split, amount	0	$ 0	$ 1	(1)	0
Balance, shares at Dec. 31, 2020		3,000,000	768,536,617
Balance, amount at Dec. 31, 2020	$ (39,803,010)	$ 3,000	$ 768,536	$ 21,315,690	$ (61,890,236)

XML 41 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2020

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company focused on immunology, urology, orthopedics and neurology using adult stem cell treatments. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing amniotic stem cells, and the treatment of neurologic disorders and lower back pain using various types of stem cells through its AmnioStem LLC, StemSpine, LLC, and ImmCelz, Inc. subsidiaries. However, neither AmnioStem LLC, StemSpine, Inc. nor ImmCelz, Inc. have commenced commercial activities.

Risks and Uncertainties - The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.

On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time consuming and could delay launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

Use of Estimates - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation - The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Going Concern - The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., which contemplate continuation of the Company as a going concern. However, during the fiscal year ended December 31, 2020, the Company incurred a net loss of $36,325,230, had negative cash flows from operating activities of $434,556, had negative working capital of $40,422,773 at December 31, 2020 and has only generate revenues for approximately 3 years. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management expects to raise additional funds through the sale of convertible notes, preferred stock, common stock and/or other securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Concentration Risks - The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at one financial institution. As of December 31, 2020, the Company’s balance did not exceed the limit.

Cash Equivalents - The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Fair Value of Financial Instrument - The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of December 31, 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations:

	Notes			Warrants		Total

Derivative liability at December 31, 2019	$	6,659,055		$	188,822	$	6,847,877
Addition of new conversion option derivatives		2,572,723			-		2,572,723
Extinguishment/modification		-			-		-
Conversion of note derivatives		(2,795,340	)		-		(2,795,340	)
Change in fair value		30,907,397			1,209,175		32,116,572
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832

Intangible Assets - Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. The impairment testing compares carrying values to fair values and, when appropriate, the carrying value of these assets is reduced to fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined.

Impairment - The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. To date no impairment has been recorded.

Derivative Liabilities - A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.

As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019, as disclosed in Notes 4 and 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis.

The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified.

Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification), and the change in fair value is recorded on our consolidated statement of operations.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.

Payments received for which the earnings process is not yet complete are deferred. As of December 31, 2020, the Company had deferred revenue of $32,000 included within current liabilities in the accompanying consolidated balance sheet.

Research and Development - Research and development will continue to be a significant function of the Company. Research and development costs will be expensed as incurred. Expenses in the accompanying financial statements include certain costs which are directly associated with the Company’s research and development:

Erectile Dysfunction Technology based upon the use of stem cells. These costs, which consist primarily of monies paid for clinical trial expenses, materials and supplies and compensation costs amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019;

Amniotic Fluid-based Stem Cells. Pre-clinical research costs, which consist primarily of monies paid for laboratory space, materials and supplies amounted to $0 for the year ended December 31, 2020. There were $0 in research costs for the period ended December 31, 2019.

Stock-Based Compensation – The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. The Company accounts for all stock-based compensation using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite vesting period. The Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates.

Income Taxes – The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred income taxes are recognized for differences between financial reporting and tax bases of assets and liabilities at the enacted statutory tax rates in effect for the years in which the temporary differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. The Company evaluates the realizability of deferred tax assets and valuation allowances are provided when necessary to reduce net deferred tax assets to the amounts expected to be realized.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company will recognize interest and penalties related to unrecognized tax benefits in the income tax provision in the accompanying statement of operations.

The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income taxes paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of relevant risks, facts and circumstances existing at that time. To the extent that the assessment of such tax positions change, the change in estimate is recorded in the period in which the determination is made.

Basic and Diluted Loss Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the year ended December 31, 2020, the Company had 3,333 options and 76,369,112 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. During the year ended December 31, 2019, the Company had 3,333 options and 5,044,260 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss.

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

XML 42 R8.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS

12 Months Ended

Dec. 31, 2020

LICENSING AGREEMENTS

NOTE 2 - LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 431,111 shares of CMTH restricted common stock valued at $100,000. CMH holds a significant amount of the Company’s common stock. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $9,972 was recorded for the years ended December 31, 2020 and 2019. As of December 31, 2020, the carrying value of the patent was $50,960. The Company expects to amortize $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of December 31, 2020, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $1,172 was recorded for the years ended December 31, 2020 and 2019. As of December 31, 2020, the carrying value of the patent was $5,256. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.

Lower Back Patent – The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $10,000 was recorded for the years ended December 31, 2020 and 2019. As of December 31, 2020, the carrying value of the initial patent license was $65,000. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

In November, 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $45,940 was recorded for the year ended December 31, 2020. Amortization expense of $5,806 was recorded for the year ended December 31, 2019. As of December 31, 2020, the carrying value of the patent was $248,254. The Company expects to amortize approximately $46,000 annually through 2027 related to the patent costs.

ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor and as documented in standard operating procedures (SOPs) and other written documentation. The terms of the agreement are as follows:

Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)

in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

As a result, the Company is obligated to pay Jadi $250,000 pursuant to the Patent License Agreement as described above.

The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Given the date of the Agreement, there was no amortization expense recorded for the year ended December 31, 2020. As of December 31, 2020, the carrying value of the patent was $250,000. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.

As of December 31, 2020, future expected amortization of these assets is as follows:

For the year ended December 31,

2021		93,327
2022		93,327
2023		93,327
2024		93,327
2025		93,327
Thereafter		152,835
Total	$	619,470

The following is a rollforward of the Company’s licensing agreements for the year end December 31, 2020.

	Assets		Accumulated Amortization

Balances at December 31, 2019	$	510,000	$	(73,445	)
Addition of new assets		250,000		-
Amortization		-		(66,792	)
Balances at December 31, 2020	$	760,000	$	(140,237	)

XML 43 R9.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	12 Months Ended
RELATED PARTY TRANSACTIONS	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
NOTE 3 - RELATED PARTY TRANSACTIONS	The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through December 31, 2020. Each of the Company’s executive officers is employed by CMH, and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH $35,000 per month for such services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH and performing services for the Company and CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. On January 12, 2018, the Company entered into a Debt Settlement Agreement with Timothy Warbington, our CEO, Chairman, and principal shareholder, and Creative Medical Health, Inc., the parent of the Company, whereby Mr. Warbington cancelled $150,000 of debt owed by CMH to him in return for which he would receive 3,000,000 shares of Series A Preferred Stock which CMH agreed to receive in return for cancellation of $150,000 of debt owed by us to CMH for management reimbursement costs. As of December 31, 2020, and 2019, amounts due to CMH under the arrangement were $18,782 and $82 respectively. During 2016, the Company entered into three note payable agreements with CMH in which the proceeds were used in operations. The notes payable were dated February 2, 2016, May 1, 2016 and May 18, 2016 and resulted in borrowings of $50,000, $50,000 and $25,000, respectively. Notes payable of $50,000 mature on April 30, 2018, $50,000 on July 31, 2018 and $25,000 on May 18, 2018. On May 4, 2017, CMT and CMH entered into a Note Extension and Limited Waiver Agreement whereby the parties extended the maturity date of the 8% Promissory Note dated February 2, 2016, in the principal amount of $50,000, from April 30, 2017, to April 30, 2018, and CMH waived the nonpayment of the Note by CMT on the original maturity date. On extension, CMT paid to CMH accrued interest related to the extended note of $4,050. On July 31, 2017, CMT and CMH entered into a Note Extension and Limited Waiver Agreement whereby the parties extended the maturity date of the 8% Promissory Note dated May 1, 2016, in the principal amount of $50,000, from July 31, 2017, to July 31, 2018, and CMH waived the nonpayment of the Note by CMT on the original maturity date. On extension, CMT paid to CMH accrued interest related to the extended note of $4,050. The notes incur interest at 8% per annum on the outstanding balance of the notes. As of December 31, 2020, accrued, unpaid interest was $0. On April 11, 2018, CMH converted $136,003 of principal and accrued interest into 9,855,290 common shares. As of December 31, 2020, the Company had fulfilled all the obligations of the notes. On August 12, 2016, CMH advanced the Company $2,000 for operations. The amount is due on demand and does not incur interest. On May 17, 2017, StemSpine, LLC (“StemSpine”), a newly formed Nevada limited liability company and wholly owned subsidiary of Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, entered into a Patent Purchase Agreement dated May 17, 2017 (the “Agreement”), with Creative Medical Holdings, Inc. (“CMH”). To date, the Company has paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 3,333,333 shares of common stock on December 12, 2019. On December 31, 2019 the Company paid CMH $50,000 of the $300,000 obligation from the second payment due under this agreement through the issuance of 66,667 shares of common stock. On September 30, 2020 the Company paid CMH $40,000 of the $300,000 obligation from the second payment due under this agreement through the issuance of 42,328,042 shares of common stock. On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. Execution of the agreement triggered a $250,000 payment obligation to Jadi. See Note 2 for discussion of an additional related party transactions with CMH relating the purchase of our ED patent in 2016, our StemSpine® patent in 2017 and the ImmCelz™ Patent License agreement in 2020.

XML 44 R10.htm IDEA: XBRL DOCUMENT

DEBT

12 Months Ended

Dec. 31, 2020

DEBT

NOTE 4 - DEBT

During 2019, we issued $1,572,400 in convertible notes to accredited investors with net proceeds of $1,302,795. The notes matured from February through October of 2020 and bore interest rates ranging from 2% to 11%. In February 2019, we entered into three separate exchange agreements with holders of common stock purchase warrants issued by the Company in September 2018 and November 2018. Under each exchange agreement, the Company issued a convertible promissory note in the principal amount of $100,000 to the warrant holder party to such exchange agreement in exchange for the cancellation of common stock purchase warrants held by such warrant holder, initially exercisable for an aggregate of 21,553 shares of the Company’s common stock. The notes were convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 66% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 20 trading days, or the volume weighted average price over the prior 15 trading days. The loans are evidenced by promissory notes and bore interest in a range of 8% to 11%. The loan maturity dates ranged from February 19, 2020 through October 11, 2020. The Company amortized the on-issuance discounts of $1,194,357 to interest expense using the straight-line method over the original terms of the loans. During 2019 the Company amortized $1,613,226 to interest expense. As of December 31, 2019, a discount of $374,124 remained.

During 2019, the Company issued an aggregate of 11,873,057 shares upon the conversion of $1,501,275 of outstanding principal, interest and fees on existing, outstanding notes and 531,247 shares upon the cashless exercise of 594,051 warrants.

During the year ended December 31, 2019, the Company incurred $41,699 in pre-payment premiums associated with the extinguishment of $313,111 in principle that was recorded as interest expense.

During 2020, we issued $831,140 in convertible notes to accredited investors with net proceeds of $710,920. The notes mature from February through December of 2021 and bear an interest rate of 8%. The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 15 trading days. The Company is amortizing the on-issuance discounts of $828,710 to interest expense using the straight-line method over the original terms of the loans. During 2020 the Company amortized $979,959 to interest expense. As of December 31, 2020, a discount of $409,650 remained.

During 2020, we issued an aggregate of 681,731,395 shares upon the conversion of $1,366,705 of outstanding principal, interest and fees on existing, outstanding notes.

As of December 31, 2020, future loan maturities are as follows:

For the year ending December 31,

2021			1,305,005

XML 45 R11.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES	12 Months Ended
DERIVATIVE LIABILITIES	Dec. 31, 2020
DERIVATIVE LIABILITIES
NOTE 5 - DERIVATIVE LIABILITIES	Derivative Liabilities In connection with convertible notes payable and the related party management fee and patent liability, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable and the related party liabilities become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the year ended December 31, 2020, the Company recorded initial derivative liabilities of $2,572,723 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.0008 to $0.0012 our stock price on the date of grant of $0.0034 to $0.0365, expected dividend yield of 0%, expected volatility of 103.79% to 131.89%, risk free interest rate of 0.16% to 1.62% and an expected term of 1.0 year. Upon initial valuation, the derivative liability exceeded the face value certain of the convertible note payables by approximately $1,864,233, which was recorded as a day one loss on derivative liability. On December 31, 2020, the derivative liabilities were revalued at $38,741,832 resulting in a loss of $33,980,805 related to the change in fair market value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.0008 to $0.0134, our stock price on the date of valuation $0.0278, expected dividend yield of 0%, expected volatility of 98.14% to 100.94%, risk-free interest rate of 0.17%, and expected terms ranging from 0.50 to 3.57 years. During the year ended December 31, 2019, the Company recorded initial derivative liabilities of $2,794,910 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.05 to $3.09, our stock price on the date of grant of $0.06 to $2.78, expected dividend yield of 0% , expected volatility of 87.61% to 103.96%, risk free interest rate of 1.56% to 2.55% and expected terms ranging from 1.0 to 5.0 years. Upon initial valuation, the derivative liability exceeded the face value certain of the convertible note payables by approximately $1,215,985, which was recorded as a day one loss on derivative liability. On December 31, 2019, the derivative liabilities were revalued at $6,847,877 resulting in a loss of $3,512,648 related to the change in fair market value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of $0.02 to $0.59, our stock price on the date of valuation $0.05, expected dividend yield of 0%, expected volatility of 93.84% to 103.96%, risk-free interest rate of 1.62%, and expected terms ranging from 0.50 to 4.58 years. Future Potential Dilution Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of December 31, 2020, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately 1.4 billion shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

XML 46 R12.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2020

STOCK-BASED COMPENSATION

NOTE 6 - STOCK-BASED COMPENSATION

The Company has reserved 13,333 shares under its 2016 Stock Incentive Plan (the “Plan”). The Plan was adopted by the board of directors on May 18, 2016, as a vehicle for the recruitment and retention of qualified employees and consultants. The Plan is administered by the Board of Directors. The Company may issue, to eligible employees or contractors, restricted common stock, options, stock appreciation rights and restricted stock units. The terms and conditions of awards under the Plan will be determined by the Board of Directors.

In July and September 2016, the Company granted 10-year options to two parties for accepting appointment to the Company’s scientific advisory board. Each award consisted of options to purchase up to 250,000 shares at $0.175 per share. The options vest at a rate of 50,000 on each anniversary date of the respective grants. The options are accounted for as non-employee stock options and thus revalued for reporting purposes at the end of each quarter. During 2020 and 2019, the fair market value of the options was insignificant to the financial statements.

Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies.

There were no options issued during the years ended December 31, 2020 and 2019.

Option activity for the years ended December 31, 2020 and 2019 consists of the following:

Stock Options

Weighted Average Exercise Price

Weighted Average Life Remaining

Outstanding, December 31, 2018

3,333

26.25

7.65

Issued

Exercised

Expired

Outstanding, December 31, 2019

3,333

26.25

6.65

Issued

Exercised

Expired

Outstanding, December 31, 2020

3,333

26.25

5.64

Vested, December 31, 2020

2,667

26.25

5.64

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 4 and 5 for discussion regarding warrants issued with a convertible note payable.

From April through September 2020, we granted 11,630,953 3-year warrants to a vendor for services rendered at exercise prices ranging from $0.0029 to $0.007. The value of the warrants was determined to be $35,670 based upon the Black-Scholes method, see variables used below. In December 2020, we granted a total of 30,000,000 warrants to three of our board members at an exercise price of $0.004. The value of the warrants was determined to be $102,081 based upon the Black-Scholes method, see variables used below. As of December 31, 2020, future estimated stock-based compensation expected to be recorded was estimated to be $0.

The fair value of each warrant award is estimated using the Black-Scholes valuation model. Assumptions used in calculating the fair value during the year ended December 31, 2020 were as follows:

	Weighted Average Inputs Used

Annual dividend yield	$	-
Expected life (years)		3.0
Risk-free interest rate		0.11% to 0.94	%
Expected volatility		95.27% to 106.51	%
Common stock price	$	0.0029 to 0.0190

See Note 7 for warrant rollforward.

XML 47 R13.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT

12 Months Ended

Dec. 31, 2020

STOCKHOLDERS DEFICIT

NOTE 7- STOCKHOLDERS' DEFICIT

During 2019, the Company entered into convertible loan agreements with third parties that included 242,841 5-year warrants to purchase a share of common stock at initial prices ranging from $0.59 to $3.09. On the date of issuance, the Company accounted for the conversion feature on the warrants as derivative liabilities, see Note 5. Derivative accounting applies as the number of warrants and the conversion price are variable and do not have a floor as to the number of common shares in which could be converted. For the year ended December 31, 2019, outstanding warrants were increased by 4,549,975 to reflect the terms of the warrant agreements. For the year ended December 31, 2019, 594,051 warrants were converted into 531,247 common shares through cashless conversions. As of December 31, 2019, 5,044,260 warrants remained.

Assumptions used in calculating the fair value of the warrants issued in 2019 were as follows:

	Range of
	Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.00
Risk-free interest rate		1.56 to 2.23	%
Expected volatility		82.85% to 92.64.00	%
Common stock price	$	0.59 to 1.52

During 2020, the Company granted 3-year warrants to three board members to purchase an aggregate of 30,000,000 share of common stock at a price of $0.004 and 8,214,286 to a contractor for services rendered at prices ranging from $0.0029 to $0.0050. For the year ended December 31, 2020, outstanding warrants were increased from the initial issuance of 145,717 warrants to 34,531,666 to reflect the terms of the existing warrant agreements. For the year ended December 31, 2020 there were no warrants converted into common shares through cashless conversions. As of December 31, 2020, 76,372,446 warrants remained.

Assumptions used in calculating the fair value of the warrants issued in 2020 were as follows:

	Range of
	Inputs Used
Annual dividend yield	$	-
Expected life (years)		3.00
Risk-free interest rate		0.11% to 0.29	%
Expected volatility		99.24% to 106.51	%
Common stock price	$	0.0029 to 0.0050

Warrant activity for the years ended December 31, 2020 and 2019 consists of the following:

	Warrants			Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2018		947,167		$	0.71		4.22
Issued		242,864
Exercises		(594,051	)
Anti-Dilution Modifications		4,549,975
Forfeiture/Cancellations		(101,695	)				-
Outstanding, December 31, 2019		5,044,260		$	0.09		3.08
Issued		41,630,953
Exercises		-
Anti-Dilution Modifications		29,697,233					-
Forfeiture/Cancellations							-
Outstanding, December 31, 2020		76,372,446		$	0.0057		2.47
Vested, December 31, 2020		76,372,446		$	0.0057		2.47

See Note 5 for discussion regarding anti-dilution and modifications related to warrants accounted for as derivative liabilities.

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements.

See Note 3 for discussion related to the issuance of common stock to a related party for cash.

XML 48 R14.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Dec. 31, 2020

INCOME TAXES

NOTE 8 - INCOME TAXES

The provision for income tax expense consists of the following at December 31, 2020 and 2019:

	2020			2019
Income tax provision attributable to:
Federal	$	(250,771	)	$	(272,800	)
State and local		(69,671	)		(75,792	)
Valuation allowance		320,442			(348,592	)
Net provision for income tax	$	-		$	-

Deferred tax assets consist of the following at December 31, 2020 and 2019:

	2020			2019
Deferred tax asset attributable to:
Net operating loss carryover	$	1,593,282		$	1,347,378
Accrued management fees, related party		155,063			80,825
Valuation allowance		(1,748,345	)		(1,427,903	)
Net deferred tax asset	$	-		$	-

The primary difference between the statutory federal rate and the Company’s effective tax rate for the years ended December 31, 2020 and 2019 was due to the 100% valuation allowance. The following is a reconciliation of the statutory federal rate and the Company’s effective tax rate for the year ended December 31, 2020 and 2019:

	2020			2019

Tax at federal statutory rate		21.0	%		21.0	%
State, net of federal benefit		0.2	%		0.9	%
Change in temporary differences		(0.0	)%		0.0	)%
Permanent differences		(20.2	)		(17.9	)%
Valuation allowance		(0.9	)%		(4.1	)%
Provision for taxes		-

As of December 31, 2020, the Company had federal and state gross net operating loss carryforwards of approximately $6.5 million. The federal and state net operating losses and tax credits expire in years beginning in 2036. Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. To date, the Company hasn’t experienced “ownership changes” under section 382 of the Code and comparable state tax laws. As of December 31, 2020, the Company estimates that none of the federal and state net operating losses will be limited under Section 382 of the Code.

As of December 31, 2020, and 2019, the Company maintained a full valuation allowance on its net deferred tax assets. The valuation allowance was determined in accordance with the provisions of ASC 740, Accounting for Income Taxes, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction by jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses required that a full valuation allowance be recorded against all net deferred tax assets. The Company intends to maintain a full valuation allowance on net deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.

The applicable federal and state rates used in calculating the deferred tax provision was 21.0% and 8.9%, respectively.

The Company files income tax returns in the U.S. and Arizona. All years presented remain subject to examination for U.S. federal and state purposes. The Company is not currently under examination in federal or state jurisdictions.

XML 49 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2019
SUBSEQUENT EVENTS
NOTE 9 - SUBSEQUENT EVENTS	On January 8, 2021 shares of common stock were issued to CMH in satisfaction of a $50,000 payment owed to CMH under the Patent Purchase Agreement, dated May 17, 2017, as amended on November 14, 2017, between us, our wholly-owned subsidiary StemSpine, LLC, and CMH. Pursuant to the Patent Agreement, the number of shares issued was calculated based on a 30% discount to the closing trading price of the common stock of $.0016 on December 9, 2020. In February 2020, we completed the sale of two 10% Original Issue Discount Senior Convertible Notes to two institutional investors pursuant to a Securities Purchase Agreement between the Company and the investors. The transactions were effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. Pursuant to the Purchase Agreements, for an aggregate purchase price of $144,500, the Investors purchased the notes in the aggregate principal amount of $157.150. The notes mature in February, 2021, bear interest at a rate of 8% per annum, and are convertible into shares of the Company’s common stock at a conversion prices ranging from to 60% to 61% of the average of the two lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date. On February 12, 2021, we completed the sale to an institutional investor 350,000 shares of the our newly designated Series B Preferred Stock pursuant to a Securities Purchase Agreement between the Company and the Purchaser for an aggregate purchase price of $350,000. In addition, pursuant to the Purchase Agreement, we issued the Purchaser 1,500,000 shares of our Common Stock as “Commitment Shares” for entering into the transaction. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506 of regulation (b) promulgated thereunder. Each share of Series B Preferred Stock has a Stated Value of $1,200.00 and is convertible into Common Stock at a conversion price equal to $0.05. The conversion price of the Series B Preferred Stock is subject to equitable adjustment in the event of a stock split, stock dividend or similar event with respect to the Common Stock, and will be reduced to $0.035 in the event of a “Triggering Event” a defined in the Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”). The Series B Preferred Stock (i) carries a quarterly dividend at the rate of 10% per annum, payable in cash or additional shares of Series B Preferred Stock, at the Company’s option, and (ii) may be redeemed by us, at its option, upon the payment of an amount equal to (a) $1,200 per share of Series B Preferred Stock, plus all accrued dividends thereon and any unpaid fees or liquidated damages then due with respect to the Series B Preferred Stock pursuant to the Certificate of Designation, multiplied by (b) a premium ranging from 5% if the redemption occurs within 90 days following the issuance of the Series B Preferred Stock, to 20% if the redemption occurs between 120 and 180 days following the issuance of the Series B Preferred Stock. On March 11, 2020, following the approval of the Board of Directors of the Company filed a Certificate of Amendment to the Certificate of Designation of the Company’s Series A Preferred Stock with the Secretary of State of the State of Nevada (the “Certificate of Amendment”). The Certificate of Amendment increased the voting power of the Series A Preferred Stock to 10,00 votes per share from 30 votes per share. The Company has 3,000,000 shares of Series A Preferred Stock outstanding, all of which are held by Timothy Warbington. From January 1, 2021 through March 17, 2021, we issued 311,702,077 shares of common stock for the conversion of $947,575 in convertible note principal, interest and fees. During January and February, 2021 we issued 10,055,556 shares to a contractor upon the conversion of 11,583,333 cashless warrants. The warrants were issued to the contractor for services rendered.

XML 50 R16.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2020

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly-owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

Risks and Uncertainties

The Company has a limited operating history and has only recently started to generate revenues from its planned principal operations.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation

The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Going Concern

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., which contemplate continuation of the Company as a going concern. However, during the fiscal year ended December 31, 2020, the Company incurred a net loss of $36,325,230, had negative cash flows from operating activities of $434,556, had negative working capital of $40,422,773 at December 31, 2020 and has only generate revenues for approximately 3 years. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management expects to raise additional funds through the sale of convertible notes, preferred stock, common stock and/or other securities.. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Concentration Risks

The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at one financial institution. As of December 31, 2020, the Company’s balance did not exceed the limit.

Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

	Notes			Warrants		Total

Derivative liability at December 31, 2019	$	6,659,055		$	188,822	$	6,847,877
Addition of new conversion option derivatives		2,572,723			-		2,572,723
Extinguishment/modification		-			-		-
Conversion of note derivatives		(2,795,340	)		-		(2,795,340	)
Change in fair value		30,907,397			1,209,175		32,116,572
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832

Intangible Assets

Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. The impairment testing compares carrying values to fair values and, when appropriate, the carrying value of these assets is reduced to fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined.

Impairment

The Company records impairment losses when indicators of impairment are present and undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. Furthermore, the Company will make periodic assessments of technology and clinical testing to determine if it plans to continue to pursue the technology and if the license, patent or other rights have value. To date no impairment has been recorded.

Derivative Liabilities

A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities.

Revenue

The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

Research and Development

Research and development will continue to be a significant function of the Company. Research and development costs will be expensed as incurred. Expenses in the accompanying financial statements include certain costs which are directly associated with the Company’s research and development:

Stock-Based Compensation

The Company accounts for its stock-based compensation in accordance with Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation. The Company accounts for all stock-based compensation using a fair-value method on the grant date and recognizes the fair value of each award as an expense over the requisite vesting period. The Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future forfeitures rates.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred income taxes are recognized for differences between financial reporting and tax bases of assets and liabilities at the enacted statutory tax rates in effect for the years in which the temporary differences are expected to reverse. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. The Company evaluates the realizability of deferred tax assets and valuation allowances are provided when necessary to reduce net deferred tax assets to the amounts expected to be realized.

Basic and Diluted Loss Per Share

The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the year ended December 31, 2019, the Company had 3,333 options and 76,369,112 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss. During the year ended December 31, 2019, the Company had 3,333 options and 5,044,260 warrants to purchase common stock outstanding; however, the effects were anti-dilutive due to the net loss.

Recent Accounting Pronouncements

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

XML 51 R17.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2020

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of Fair Value

	Notes			Warrants		Total

Derivative liability at December 31, 2019	$	6,659,055		$	188,822	$	6,847,877
Addition of new conversion option derivatives		2,572,723			-		2,572,723
Extinguishment/modification		-			-		-
Conversion of note derivatives		(2,795,340	)		-		(2,795,340	)
Change in fair value		30,907,397			1,209,175		32,116,572
Derivative liability at December 31, 2020	$	37,343,835		$	1,397,997	$	38,741,832

XML 52 R18.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Tables)

12 Months Ended

Dec. 31, 2020

LICENSING AGREEMENTS

Schedule of licensing agreements

	Assets		Accumulated Amortization

Balances at December 31, 2019	$	510,000	$	(73,445	)
Addition of new assets		250,000		-
Amortization		-		(66,792	)
Balances at December 31, 2020	$	760,000	$	(140,237	)

Schedule of future expected amortization

For the year ended December 31,

2021		93,327
2022		93,327
2023		93,327
2024		93,327
2025		93,327
Thereafter		152,835
Total	$	619,470

XML 53 R19.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

12 Months Ended

Dec. 31, 2020

DEBT

Schedule of future loan maturities

For the year ending December 31,

2021			1,305,005

XML 54 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2020

STOCK-BASED COMPENSATION

Schedule of Warrants

Stock Options

Weighted Average Exercise Price

Weighted Average Life Remaining

Outstanding, December 31, 2018

3,333

26.25

7.65

Issued

Exercised

Expired

Outstanding, December 31, 2019

3,333

26.25

6.65

Issued

Exercised

Expired

Outstanding, December 31, 2020

3,333

26.25

5.64

Vested, December 31, 2020

2,667

26.25

5.64

Schedule of fair value of warrants

	Weighted Average Inputs Used

Annual dividend yield	$	-
Expected life (years)		3.0
Risk-free interest rate		0.11% to 0.94	%
Expected volatility		95.27% to 106.51	%
Common stock price	$	0.0029 to 0.0190

XML 55 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Tables)

12 Months Ended

Dec. 31, 2020

STOCKHOLDERS DEFICIT

Schedule of Stockholders Deficit

	Range of
	Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.00
Risk-free interest rate		1.56 to 2.23	%
Expected volatility		82.85% to 92.64.00	%
Common stock price	$	0.59 to 1.52

	Range of
	Inputs Used
Annual dividend yield	$	-
Expected life (years)		3.00
Risk-free interest rate		0.11% to 0.29	%
Expected volatility		99.24% to 106.51	%
Common stock price	$	0.0029 to 0.0050

Schedule of warrant activity

	Warrants			Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2018		947,167		$	0.71		4.22
Issued		242,864
Exercises		(594,051	)
Anti-Dilution Modifications		4,549,975
Forfeiture/Cancellations		(101,695	)				-
Outstanding, December 31, 2019		5,044,260		$	0.09		3.08
Issued		41,630,953
Exercises		-
Anti-Dilution Modifications		29,697,233					-
Forfeiture/Cancellations							-
Outstanding, December 31, 2020		76,372,446		$	0.0057		2.47
Vested, December 31, 2020		76,372,446		$	0.0057		2.47

XML 56 R22.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2020

INCOME TAXES

Schedule of income taxes

	2020			2019
Income tax provision attributable to:
Federal	$	(250,771	)	$	(272,800	)
State and local		(69,671	)		(75,792	)
Valuation allowance		320,442			(348,592	)
Net provision for income tax	$	-		$	-

Schedule of deferred tax assets

	2020			2019
Deferred tax asset attributable to:
Net operating loss carryover	$	1,593,282		$	1,347,378
Accrued management fees, related party		155,063			80,825
Valuation allowance		(1,748,345	)		(1,427,903	)
Net deferred tax asset	$	-		$	-

Schedule of effective tax rate

	2020			2019

Tax at federal statutory rate		21.0	%		21.0	%
State, net of federal benefit		0.2	%		0.9	%
Change in temporary differences		(0.0	)%		0.0	)%
Permanent differences		(20.2	)		(17.9	)%
Valuation allowance		(0.9	)%		(4.1	)%
Provision for taxes		-			-

XML 57 R23.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Derivative liability, beginning	$ 6,847,877
Addition of new conversion option derivatives	2,572,723
Conversion of note derivatives	(2,795,340)
Change in fair value	32,116,572
Derivative liability, ending	38,741,832	$ 6,847,877
Extinguishment/modification		313,111
Warrant [Member]
Derivative liability, beginning	188,822
Addition of new conversion option derivatives	0
Conversion of note derivatives	0
Change in fair value	1,209,175
Derivative liability, ending	1,397,997	188,822
Extinguishment/modification	0
Notes [Member]
Derivative liability, beginning	6,659,055
Addition of new conversion option derivatives	2,572,723
Conversion of note derivatives	(2,795,340)
Change in fair value	30,907,397
Derivative liability, ending	37,343,835	$ 6,659,055
Extinguishment/modification	$ 0

XML 58 R24.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Working capital deficit	$ 40,422,773
Research costs	0	$ 0
Materials and supplies and compensation costs	0	0
Deferred revenue	32,000
Net loss	(36,325,230)	(8,483,673)
Cash used in operating activity	$ (434,556)	$ (1,213,093)
Warrant [Member]
Anti-dilutive securities excluded from computation of earning per share		5,044,260
Warrants to purchase common stock		76,369,112
Options [Member]
Anti-dilutive securities excluded from computation of earning per share		3,333
Options to purchase common stock		3,333

XML 59 R25.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details)	Dec. 31, 2020 USD ($)
LICENSING AGREEMENTS
2021	$ 93,327
2022	93,327
2023	93,327
2024	93,327
2025	93,327
Thereafter	152,835
Total	$ 619,470

XML 60 R26.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details 1)	12 Months Ended
LICENSING AGREEMENTS (Details 1)	Dec. 31, 2020 USD ($)
Assets
Beginning Balance	$ 510,000
Addition of new assets	250,000
Amortization	0
Ending Balance	760,000
Accumulated Amortization
Accumulated Amortization, Beginning Balance	(73,445)
Addition of new assets	0
Amortization	(66,792)
Accumulated Amortization, Ending Balance	$ (140,237)

XML 61 R27.htm IDEA: XBRL DOCUMENT

LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended				12 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Dec. 28, 2020	Nov. 30, 2019	May 17, 2017	Feb. 02, 2016	Dec. 31, 2020	Dec. 31, 2019
Stock Issued During Period, Shares, Purchase of Assets				431,111
Stock Issued During Period, Value, Purchase of Assets				$ 100,000
License fees	$ 250,000
License agreement description	Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
Continuing royalty description					Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz. during such calendar quarter (the “Continuing Royalty”)
Patent cost					$ 619,763	$ 436,555
Amortization of Intangible Assets					66,792	26,950
Stemspine LLC [Member]
Royalty payment percentage			5.00%
Non-royalty sublease income percentage.			50.00%
Patents [Member]
Patent cost					$ 50,960
Expiration period of finite-lived intangible assets					2025
Amortization of Intangible Assets						5,806
Expected amount of amortization					$ 9,972
Patents [Member] \| Creative Medical Health Inc [Member]
Patent cost					$ 248,254
Expiration period of finite-lived intangible assets					2027
Amortization of Intangible Assets					$ 45,940	9,972
Expected amount of amortization					46,000
Initial payment		$ 300,000	$ 100,000
Percentage of discount on the basis of recent trading price			30.00%
Share price for two or more consecutive trading days			$ 0.01
Patents [Member] \| Creative Medical Health Inc [Member] \| Scenario One [Member]
Payments upon signing agreement with university for the initiation of an IRB clinical trial			$ 100,000
Payments upon completion of the IRB clinical trial			200,000
Payments in the event of commercialization of technology			300,000
Patents [Member] \| Creative Medical Health Inc [Member] \| Scenario Two [Member]
Payments upon filing an IND with the FDA			100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial			200,000
Payments upon dosing of the first patient in Phase 3 clinical trial			$ 400,000
Patents [Member] \| Stemspine LLC [Member]
Patent cost					$ 65,000
Expiration period of finite-lived intangible assets					2027
Amortization of Intangible Assets					$ 10,000	10,000
Expected amount of amortization					$ 10,000
Patent License Agreement [Member]
Amortization period					10 years
Patent cost					$ 25,000
Expiration period of finite-lived intangible assets					2030
Patent, carrying value					$ 250,000
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] \| Patents [Member]
Patent cost					$ 5,256
Expiration period of finite-lived intangible assets					2026
Amortization of Intangible Assets					$ 1,172	$ 1,172
Expected amount of amortization					$ 1,172

XML 62 R28.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)					1 Months Ended						12 Months Ended
	Dec. 12, 2019	Apr. 11, 2018	May 04, 2017	Aug. 12, 2016	Dec. 28, 2020	Sep. 30, 2020	Dec. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Nov. 17, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2016
Agreement description					the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a Board Member. Execution of the agreement triggered a $250,000 payment obligation to Jadi.
Proceeds from Related Party Debt				$ 2,000
Debt Conversion, Converted Instrument, Shares Issued											14,000,000,000
Creative Medical Health [Member]
Reimbursement of management fees							$ 45,000			$ 35,000
Management and consultant service										$ 35,000
Percentage of Common Stock										30.00%
Number of Trading days										20 days
Agreement Notice period										30 days
Debt Conversion, Original Debt, Amount		$ 136,003
Debt Conversion, Converted Instrument, Shares Issued		9,855,290
Amounts due under the arrangement											$ 18,782	$ 82
Interest Payable, Current												0
Long-term Purchase Commitment, Amount	$ 100,000					$ 40,000						50,000
Cash payment	$ 50,000					$ 300,000						$ 300,000
Issuance of shares of common stock	3,333,333					42,328,042						66,667
Creative Medical Health [Member] \| February Note [Member]
Interest Payable, Current			$ 4,050
Line of Credit Facility, Initiation Date													Feb. 02, 2016
Proceeds from Lines of Credit													$ 50,000
Line of Credit Facility, Maximum Borrowing Capacity			$ 50,000										$ 50,000
Line of Credit Facility, Expiration Date													Apr. 30, 2018
Line of Credit Facility, Interest Rate During Period			8.00%
Creative Medical Health [Member] \| May Note One [Member]
Interest Payable, Current								$ 4,050
Line of Credit Facility, Initiation Date								Jul. 31, 2017					May 01, 2016
Proceeds from Lines of Credit													$ 50,000
Line of Credit Facility, Maximum Borrowing Capacity								$ 50,000	$ 50,000				$ 50,000
Line of Credit Facility, Expiration Date								Jul. 31, 2018	Apr. 30, 2018				Jul. 31, 2018
Line of Credit Facility, Interest Rate During Period								8.00%
Creative Medical Health [Member] \| May Note Two [Member]
Line of Credit Facility, Initiation Date													May 18, 2016
Proceeds from Lines of Credit													$ 25,000
Line of Credit Facility, Maximum Borrowing Capacity													$ 25,000
Line of Credit Facility, Expiration Date													May 18, 2018

XML 63 R29.htm IDEA: XBRL DOCUMENT

DEBT (Details)	Dec. 31, 2020 USD ($)
DEBT
2021	$ 1,305,005

XML 64 R30.htm IDEA: XBRL DOCUMENT

DEBT (Details Narrative)	1 Months Ended	12 Months Ended
DEBT (Details Narrative)	Feb. 29, 2020	Dec. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($) integer shares
Pre-payment premiums associated with the extinguishment			$ 41,699
Amortizing on issuance discount to interest expense		$ 828,710
Extinguishment recorded			313,111
Remaining discount, amount		409,650
Interest expense		$ 1,229,590	$ 1,895,528
Number of shares issued upon conversion of debt \| shares		681,731,395	11,873,057
Debt conversion, amount		$ 1,366,705	$ 1,501,275
Common stock issued for cashless warrant exercise (In Shares) \| shares			531,247
Warrants exercises			$ 0
Proceeds from Convertible Debt		710,920	1,302,795
Debt Instrument, Interest Rate During Period	8.00%
Original issue discount		979,960	1,723,451
Convertible Notes Payable [Member]
Convertible notes issued		831,140	1,572,400
Proceeds from Convertible Debt		$ 710,920	$ 1,302,795
Debt Instrument, Interest Rate During Period		8.00%	8.00%
Amortization of Debt Issuance Costs			$ 1,613,226
Debt instrument descriptions		The notes are convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 71% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 15 trading days.	The notes were convertible into shares of the Company’s common stock at conversion prices ranging from 60% to 66% of the average of the two lowest traded prices of the Company’s common stock during the previous 15 trading days preceding the conversion date, the lowest trade price during the previous 20 trading days, or the volume weighted average price over the prior 15 trading days.
Original issue discount			$ 1,194,357
Cancellation of common stock purchase \| shares			21,533
Convertible Notes Payable [Member] \| Maximum [Member]
Debt Instrument, Interest Rate During Period			11.00%
Debt Instrument, Convertible, Conversion Percentage		60.00%	66.00%
Convertible Notes Payable [Member] \| Minimum [Member]
Debt Instrument, Interest Rate During Period			2.00%
Debt Instrument, Convertible, Conversion Percentage		71.00%	60.00%
Promissory Notes [Member]
Convertible notes issued			$ 100,000
Debt Instrument, Unamortized Discount			$ 374,124
Debt Instrument, Convertible, Threshold Consecutive Trading Days \| integer			15
Promissory Notes [Member] \| Maximum [Member]
Debt Instrument, Interest Rate During Period			11.00%
Promissory Notes [Member] \| Minimum [Member]
Debt Instrument, Interest Rate During Period			8.00%

XML 65 R31.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	12 Months Ended
DERIVATIVE LIABILITIES (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Initial Derivative Liability	$ 2,572,723	$ 2,794,910
Debt Conversion, Converted Instrument, Shares Issued	14,000,000,000
Convertible debt	$ 1,864,233	1,215,985
Derivative, Gain (Loss) on Derivative, Net	$ (33,980,805)	$ (5,091,935)
Minimum [Member]
Shares Price	$ 0.0034	$ 0.06
Minimum [Member] \| Employee Stock Option [Member]
Fair Value Assumptions, Expected Term	5 years 18 days	5 months 30 days
Minimum [Member] \| Measurement Input Price Volatility [Member]
Derivative Liability, Measurement Input Percentage	103.79%	87.61%
Minimum [Member] \| Measurement Input Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input Ratio	0.16	1.56
Minimum [Member] \| Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio	0.0008	0.05
Minimum [Member] \| Measurement Input Expected Term [Member]
Derivative Liability, Measurement Input Ratio	1.0	1.0
Maximum [Member]
Shares Price	$ 0.0365	$ 2.78
Maximum [Member] \| Employee Stock Option [Member]
Fair Value Assumptions, Expected Term	5 years 2 months 27 days
Maximum [Member] \| Measurement Input Price Volatility [Member]
Derivative Liability, Measurement Input Percentage	131.89%	103.96%
Maximum [Member] \| Measurement Input Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input Percentage	1.62%	2.55%
Maximum [Member] \| Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio	0.0012	3.09
Revaluation [Member]
Derivative, Gain (Loss) on Derivative, Net	$ 33,980,805	$ 3,512,648
Derivative Liability	$ 38,741,832	$ 6,847,877
Revaluation [Member] \| Minimum [Member] \| Measurement Input Price Volatility [Member]
Derivative Liability, Measurement Input Percentage	98.14%	93.84%
Revaluation [Member] \| Minimum [Member] \| Measurement Input Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input Percentage	0.16%	1.62%
Revaluation [Member] \| Minimum [Member] \| Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio	0.0008	0.02
Revaluation [Member] \| Minimum [Member] \| Measurement Input Expected Term [Member]
Derivative Liability, Measurement Input Ratio	0.0278	0.05
Revaluation [Member] \| Maximum [Member] \| Measurement Input Price Volatility [Member]
Derivative Liability, Measurement Input Percentage	100.94%	103.96%
Revaluation [Member] \| Maximum [Member] \| Measurement Input Exercise Price [Member]
Derivative Liability, Measurement Input Ratio	0.0134	0.59

XML 66 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - $ / shares	12 Months Ended
STOCK-BASED COMPENSATION (Details) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Warrants, Exercised		531,247
Option [Member]
Warrants, Outstanding at the begining	3,333	3,333
Warrants, Issued
Warrants, Exercised
Warrants, Expired
Warrants, Outstanding at the end	3,333	3,333
Warrants, Vested	2,667
Weighted Average Exercise Price, Outstanding beginning	$ 26.25	$ 26.25
Weighted Average Exercise Price, Outstanding ending	26.25	$ 26.25
Weighted Average Exercise Price, Vested	$ 26.25
Weighted Average Life Remaining, Outstanding beginning		7 years 7 months 24 days
Weighted Average Life Remaining, Outstanding ending	5 years 7 months 21 days	6 years 7 months 24 days
Weighted Average Life Remaining, Vested	5 years 7 months 21 days

XML 67 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Annual dividend yield	0.00%	0.00%
Expected life (years)	3 years	5 years
Minimum [Member]
Risk-free interest rate	0.11%
Common stock price	$ 0.0029
Expected volatility	95.27%
Maximum [Member]
Risk-free interest rate	0.94%	2.23%
Common stock price	$ 0.0190	$ 1.52
Expected volatility	106.51%	92.64%

XML 68 R34.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Sep. 30, 2016	Dec. 31, 2020	Dec. 31, 2019	May 18, 2016
Allocated Share-based Compensation Expense		$ 102,081	$ 0
Fair value of warrants		$ 35,670
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.175
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		The options vest at a rate of 50,000 on each anniversary date of the respective grants.
Stock Incentive Plan2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				13,333
Maximum [Member]
Exercise price		$ 0.007
Minimum [Member] \| April To September, 2020 [Member]
Exercise price		$ 0.0029
Warrants granted		11,630,953
Warrant descriptions		we granted a total of 30,000,000 warrants to 3 of our board members at an exercise price of $0.004

XML 69 R35.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Details) - $ / shares	12 Months Ended
STOCKHOLDERS DEFICIT (Details) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Warrants [Member]
Annual dividend yield	0.00%	0.00%
Expected life (years)	3 years	5 years
Warrants [Member] \| Maximum [Member]
Risk-free interest rate	0.94%	2.23%
Expected volatility	106.51%	92.64%
Common stock price	$ 0.0190	$ 1.52
Warrant One \| Minimum [Member]
Risk-free interest rate	0.11%	1.56%
Expected volatility	99.24%	82.85%
Common stock price	$ 0.0029	$ 0.59

XML 70 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Details 1) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warrants, Outstanding Beginning Balance	5,044,260	947,167
Warrants, Issued	41,630,953	242,864
Warrants, Exercised		(594,051)
Anti-Dilution Modifications	29,697,233	4,549,975
Forfeiture/Cancellations	0	(101,695)
Warrants, Outstanding Ending Balance	76,372,446	5,044,260
Warrants, Vested	76,372,446
Weighted Average Exercise Price, Outstanding beginning	$ 0.09	$ 0.71
Weighted Average Exercise Price, Outstanding ending	0.0057	$ 0.09
Weighted Average Exercise Price, Vested	$ 0.0057
Weighted Average Life Remaining, Outstanding Beginning	3 years 29 days	4 years 2 months 19 days
Weighted Average Life Remaining, Outstanding Ending	2 years 5 months 19 days	3 years 29 days
Weighted Average Life Remaining, Vested	2 years 5 months 19 days

XML 71 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Details Narrative) - $ / shares	12 Months Ended
STOCKHOLDERS DEFICIT (Details Narrative) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Warrant One \| Minimum [Member]
Common stock price	$ 0.0029	$ 0.59
Convertible Loan Agreement [Member]
Shares issued upon exercise of warrants, shares	30,000,000	242,841
Warrant term	3 years	5 years
Convertible Loan Agreement [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0050	$ 3.09
Convertible Loan Agreement [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0029	$ 0.59
Convertible Loan Agreement [Member] \| Warrant Agreement [Member]
Number of increased warrants as per the warrant agreement		4,549,975
Convertible Loan Agreement [Member] \| Warrant One
Warrant descriptions	outstanding warrants were increased from the initial issuance of 145,717 warrants to 34,531,666 to reflect the terms of the warrant agreement.
Common stock price	$ 0.004
Class of Warrant or Right, Outstanding	76,372,446
Convertible Loan Agreement [Member] \| Warrant Two [Member]
Class of Warrant or Right, Outstanding		5,044,260
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	8,214,286	531,247
Class of warrant or right converted into common shares		594,051

XML 72 R38.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($)	12 Months Ended
INCOME TAXES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Federal	$ (250,771)	$ (272,800)
State and local	(69,671)	(75,792)
Valuation allowance	320,442	(348,592)
Net provision for income taxes	$ 0	$ 0

XML 73 R39.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Net operating loss carryover	$ 1,593,282	$ 1,347,378
Accrued management fees, related party	155,063	80,525
Valuation allowance	(1,748,345)	(1,427,903)
Net deferred tax asset	$ 0	$ 0

XML 74 R40.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 2)	12 Months Ended
INCOME TAXES (Details 2)	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Tax at federal statutory rate	21.00%	21.00%
State, net of federal benefit	0.20%	0.90%
Change in temporary differences	(0.00%)	(0.00%)
Permanent differences	(20.20%)	(17.90%)
Valuation allowance	(0.90%)	(4.10%)
Provision for taxes	0.00%	0.00%

XML 75 R41.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Federal and state net operating carry forward loss		$ 6,500,000
Deferred income tax provision percent	21.00%	21.00%
Patents [Member]
Expiration period of finite-lived intangible assets	2025
Domestic Country [Member]
Deferred income tax provision percent	21.00%
State And Local Jurisdiction [Member]
Deferred income tax provision percent	8.90%

XML 76 R42.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			1 Months Ended		2 Months Ended	3 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Dec. 09, 2020	Mar. 11, 2020	Jan. 08, 2021	Feb. 29, 2020	Feb. 28, 2021	Mar. 31, 2021	Dec. 31, 2020	Feb. 12, 2021	Dec. 31, 2019
Debt Instrument, Interest Rate During Period				8.00%
Common Stock shares issued							768,540,617		22,493,046
Debt conversion, converrted instrument, shares issued							14,000,000,000
Subsequent Event [Member] \| Convertible Note [Member]
Debt conversion, converrted instrument, shares issued						311,702,077
Debt conversion, converrted instrument, amount						$ 947,575
Purchase Agreements [Member]
Common Stock shares issued								1,500,000
Aggregate purchase price				$ 144,500
Principal amount				$ 157,150
Debt instrument descriptions				Convertible into shares of the Company’s common stock at a conversion prices ranging from to 60% to 61% of the average of the two lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date.
Maturity date description				The notes mature in February, 2021, bear interest at a rate of 8% per annum
Series B Preferred Stock [Member]
Stated Value per share							$ 1,200
Conversion price per share							$ 0.05
Preferred stock redemption terms							The Series B Preferred Stock (i) carries a quarterly dividend at the rate of 10% per annum, payable in cash or additional shares of Series B Preferred Stock, at the Company’s option, and (ii) may be redeemed by us, at its option, upon the payment of an amount equal to (a) $1,200 per share of Series B Preferred Stock, plus all accrued dividends thereon and any unpaid fees or liquidated damages then due with respect to the Series B Preferred Stock pursuant to the Certificate of Designation, multiplied by (b) a premium ranging from 5% if the redemption occurs within 90 days following the issuance of the Series B Preferred Stock, to 20% if the redemption occurs between 120 and 180 days following the issuance of the Series B Preferred Stock.
Series A Preferred Stock [Member]
Preferred stock voting right		The Certificate of Amendment increased the voting power of the Series A Preferred Stock to 10,00 votes per share from 30 votes per share.
Preferred stock shares outstanding		3,000,000
Creative Medical Health [Member]
Payments of related party			$ 50,000
Discount rate	30.00%
Common stock price per share	$ .0016
Institutional Investor [Member] \| Series B Preferred Stock [Member] \| Subsequent Event [Member]
Aggregate purchase price								$ 350,000
Preferred stock shares designated								350,000
Contractor [Member] \| Subsequent Event [Member] \| Warrant One
Debt conversion, converrted instrument, shares issued					10,055,556
Common stock issued for cashless warrant exercise, shares					11,583,333

EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-8?2 M0$3;8T.P6BP^0"X99K>]9!:GUN!&%T+^&3ON[X XI M125*\&\9Z;/V]+=UJ>BT)S-6::3Y2\VXCJMKF-Z44/ M=*.-P^ZZ#>*9^I\PRM5*+/A8+NY*7NEM'!4O&L"J7HM-[9"*E7SH!/*>JZ8_ MY@'1C5Y:6??FLIHPF _(! ?K +.8V" M,,ZB>$+\21INPPC(3A"R$[MD:3AMAW?FI_DWDJ=^G/E!$TO(=XKPG=KE&X>C M'&;G/I:>^[99TFAN7K1Y2*:1/XJF41Z%,$XN*@_+]FBFY.=W(S\SHQDDES/S MPK63 O)A[G MRZ/ENTBF)HH9&8?G41#MC2RF#->R,Z+81"PDN?]U?SPQ0[B6 M%9%=C;+PRU7CKG#^5\)P,2NXEK6 9MQK#V)B7G /*89K"C$Q,[@'4 -Y8Q;* M!:_?0DA,$JYE2S19N!,*,X-K60TO);PG4+ADQJSA6;9&5][KBJ6'R<.S+ ^8 M #OAT%V'97/@,WD ,3&)>)8E@F,>04S,*YYEKW0GG#'73!3[8XY)QK,L&922 MN! 3DXQG63(X)EQ[>9AD/,N2>7F5W\)"3$PSWJMHINM5Q#SCO<(6!(PI4XHU M9UF0CV*"H0?9ECP30TQ,,?1 ^Y,G4(B)R8:^QC;E)S<3OQ D1;,8(0 MNB>CMQ^C"_W(+&9C^EN1;D+Q)B1/""R^?%7$8W,.Y;$-@TM=G<,R*V-L/YP+ MV]+711@VK3_?SNR;KB[B;=D=7%ML3\7!.QV-)JY[G9&M%J\S!YMKZ_\SL=GO MCUO_V6R_:W^.?PQV/TUW"J7W,1MLBN[@XS)SE^JY'=S](,/;Y&RPWBVS;KV3 MS*4.4@C2]$$&098^*(>@/'W0&(+&Z8,F$#1)'S2%H&GZH!D$S=('S2%HGCY( M1BCCB""IAS6!UH)<"X'7@F +@=B"9 N!V8)H"X':@FP+@=N"< N!W()T"X'= M@G@+@=Z*>BN!WHIZ*X'>VGO9)M!;46\ET%M1;R706U%O)=!;46\ET%M1;R70 M6U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-MZ'TL(]#;4VPCT-M3;"/0VU-L( M]#;4VPCT-M3;"/0VU-L(],Y1[YQ [QSUS@GTSE'O_)UZAWBM?'CV/-9X_W=2 M'6_7^N?M[\O'9N^YW'%V\)=E]0M02P,$% @ 18MQ4B/5;@VH 0 N!D M !, !;0V]N=&5N=%]4>7!E&ULS9G-;L(P$(1?!>6*B+&=TA\!E[;7 MED-?P$TV)"*)+=M0>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV==6X651X M;QX8#QAJ6X\-7[D6XUH/GVB7*TK M/WC>AL^NU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-*TKCAJ$@ M8F<=VIV?#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE.EW7H25V MQI+*7$'DZRK>BP[[G7VX8=H_^=7^G4R?8:A<6&U) O57_]+:->X5F5S]&?=#YOY)U!+ M 0(4 Q0 ( $6+<5('04UB@0 +$ 0 " 0 !D M;V-0&UL4$L! A0#% @ 18MQ4O$T:1GO *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ M18MQ4IE$ & M @($." >&PO=V]R:W-H965T&UL4$L! A0#% @ M18MQ4HY5?<^)!0 110 !@ ("!IPP 'AL+W=O($ <$ & @($G%@ >&PO=V]R M:W-H965T&UL4$L! A0#% @ 18MQ4I(AAB/P!@ 2QL M !@ ("!/QL 'AL+W=O75 (2 M #'+@ & @($7*0 >&PO=V]R:W-H965T&UL4$L! A0#% @ 18MQ4E<#IJLV"0 'QH !@ ("! M3SL 'AL+W=OL@% !0$ &0 M @($.3@ >&PO=V]R:W-H965T&UL4$L! A0#% @ 18MQ4IBJ&@(S!@ J@X !D M ("!$%H 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 18MQ4@CRV^S(!P :A0 !D ("! M!6X 'AL+W=OQRA < 950 &0 @($$=@ >&PO=V]R:W-H965T&UL4$L! A0#% M @ 18MQ4D=L+[F_ @ 708 !D ("!=I4 'AL+W=O&UL4$L! A0#% @ 18MQ4H'Q"EU_ M P 2P@ !D ("!ZYT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 18MQ4H#F1ABK P [ H !D M ("!8*D 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 18MQ4C)4]C?F!P >R( !D ("!AK( M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M18MQ4C$.WCVK!@ SQP !D ("!OL, 'AL+W=OH% #D'@ &0 M @(&@R@ >&PO=V]R:W-H965T'&UL4$L! A0#% @ 18MQ4GFW@D,7 P M) H !D ("!;M0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 18MQ4A".^D+, P I T !D M ("!U-\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 18MQ4B852PYR @ 2 8 !D ("!)NL 'AL M+W=O&PO=V]R:W-H965T3(2\Y@( '<( 9 " M@
&UL4$L! A0#% @ 18MQ M4EELZVY/!P 21L !D ("!X/, 'AL+W=O&PO/] !?&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" !%BW%2(]5N#:@! "X&0 $P @ %I! $ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 ,@ R )4- !"!@$ ! end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 183 366 1 false 50 0 false 5 false false R1.htm 000001 - Document - Cover Sheet http://jolleymarketing.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://jolleymarketing.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://jolleymarketing.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://jolleymarketing.com/role/ConsolidatedStatementOfOperations CONSOLIDATED STATEMENT OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://jolleymarketing.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Sheet http://jolleymarketing.com/role/ConsolidatedStatementsOfStockholdersDeficit CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LICENSING AGREEMENTS Sheet http://jolleymarketing.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 8 false false R9.htm 000009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://jolleymarketing.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 000010 - Disclosure - DEBT Sheet http://jolleymarketing.com/role/DEBT DEBT Notes 10 false false R11.htm 000011 - Disclosure - DERIVATIVE LIABILITIES Sheet http://jolleymarketing.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 11 false false R12.htm 000012 - Disclosure - STOCK-BASED COMPENSATION Sheet http://jolleymarketing.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 12 false false R13.htm 000013 - Disclosure - STOCKHOLDERS DEFICIT Sheet http://jolleymarketing.com/role/StockholdersDeficit STOCKHOLDERS DEFICIT Notes 13 false false R14.htm 000014 - Disclosure - INCOME TAXES Sheet http://jolleymarketing.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://jolleymarketing.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 17 false false R18.htm 000018 - Disclosure - LICENSING AGREEMENTS (Tables) Sheet http://jolleymarketing.com/role/LicensingAgreementsTables LICENSING AGREEMENTS (Tables) Tables http://jolleymarketing.com/role/LicensingAgreements 18 false false R19.htm 000019 - Disclosure - DEBT (Tables) Sheet http://jolleymarketing.com/role/DebtTables DEBT (Tables) Tables http://jolleymarketing.com/role/DEBT 19 false false R20.htm 000020 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://jolleymarketing.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://jolleymarketing.com/role/StockBasedCompensation 20 false false R21.htm 000021 - Disclosure - STOCKHOLDERS DEFICIT (Tables) Sheet http://jolleymarketing.com/role/StockholdersDeficitTables STOCKHOLDERS DEFICIT (Tables) Tables http://jolleymarketing.com/role/StockholdersDeficit 21 false false R22.htm 000022 - Disclosure - INCOME TAXES (Tables) Sheet http://jolleymarketing.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://jolleymarketing.com/role/IncomeTaxes 22 false false R23.htm 000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://jolleymarketing.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 000025 - Disclosure - LICENSING AGREEMENTS (Details) Sheet http://jolleymarketing.com/role/LicensingAgreementsDetails LICENSING AGREEMENTS (Details) Details http://jolleymarketing.com/role/LicensingAgreementsTables 25 false false R26.htm 000026 - Disclosure - LICENSING AGREEMENTS (Details 1) Sheet http://jolleymarketing.com/role/LicensingAgreementsDetails1 LICENSING AGREEMENTS (Details 1) Details http://jolleymarketing.com/role/LicensingAgreementsTables 26 false false R27.htm 000027 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://jolleymarketing.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://jolleymarketing.com/role/LicensingAgreementsTables 27 false false R28.htm 000028 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://jolleymarketing.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://jolleymarketing.com/role/RelatedPartyTransactions 28 false false R29.htm 000029 - Disclosure - DEBT (Details) Sheet http://jolleymarketing.com/role/DebtDetails DEBT (Details) Details http://jolleymarketing.com/role/DebtTables 29 false false R30.htm 000030 - Disclosure - DEBT (Details Narrative) Sheet http://jolleymarketing.com/role/DebtDetailsNarrative DEBT (Details Narrative) Details http://jolleymarketing.com/role/DebtTables 30 false false R31.htm 000031 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://jolleymarketing.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://jolleymarketing.com/role/DerivativeLiabilities 31 false false R32.htm 000032 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://jolleymarketing.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://jolleymarketing.com/role/StockBasedCompensationTables 32 false false R33.htm 000033 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://jolleymarketing.com/role/StockBasedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://jolleymarketing.com/role/StockBasedCompensationTables 33 false false R34.htm 000034 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://jolleymarketing.com/role/StockBasedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://jolleymarketing.com/role/StockBasedCompensationTables 34 false false R35.htm 000035 - Disclosure - STOCKHOLDERS DEFICIT (Details) Sheet http://jolleymarketing.com/role/StockholdersDeficitDetails STOCKHOLDERS DEFICIT (Details) Details http://jolleymarketing.com/role/StockholdersDeficitTables 35 false false R36.htm 000036 - Disclosure - STOCKHOLDERS DEFICIT (Details 1) Sheet http://jolleymarketing.com/role/StockholdersDeficitDetails1 STOCKHOLDERS DEFICIT (Details 1) Details http://jolleymarketing.com/role/StockholdersDeficitTables 36 false false R37.htm 000037 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) Sheet http://jolleymarketing.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS DEFICIT (Details Narrative) Details http://jolleymarketing.com/role/StockholdersDeficitTables 37 false false R38.htm 000038 - Disclosure - INCOME TAXES (Details) Sheet http://jolleymarketing.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://jolleymarketing.com/role/IncomeTaxesTables 38 false false R39.htm 000039 - Disclosure - INCOME TAXES (Details 1) Sheet http://jolleymarketing.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://jolleymarketing.com/role/IncomeTaxesTables 39 false false R40.htm 000040 - Disclosure - INCOME TAXES (Details 2) Sheet http://jolleymarketing.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://jolleymarketing.com/role/IncomeTaxesTables 40 false false R41.htm 000041 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://jolleymarketing.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://jolleymarketing.com/role/IncomeTaxesTables 41 false false R42.htm 000042 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://jolleymarketing.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://jolleymarketing.com/role/SubsequentEvents 42 false false All Reports Book All Reports celz-20201231.xml celz-20201231.xsd celz-20201231_cal.xml celz-20201231_def.xml celz-20201231_lab.xml celz-20201231_pre.xml http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 82 0001477932-21-001495-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-21-001495-xbrl.zip M4$L#!!0 ( $6+<5*.P&88*;X $&7" 1 8V5L>BTR,#(P,3(S,2YX M;6SL?6ESXT:2Z/>-V/^ U]/>L"- -L";W3-^H9;4MF;Z4+3D\>[[L@$111%C M$*!QZ)A?_S*SJH ""%"\"5*8&-L4"51E969EY569?_V_3U-7>V!!Z/C>W]Z8 M3>.-QKR1;SO>_=_>Q&'#"D>.\T8+(\NS+=?WV-_>/+/PS?_]^3__XZ__I]'X M[X_?/VL7_BB>,B_2S@-F1'5C:/YK:#7PS2<8X]V?/@7,_B;0?1S]I M.+QVU?AZ>:M]C$/'8V&HW?ANC""$NG;EC9K:F>MJW_&-4/O.0A8\,+O)AWNZ M"USG/?Y; ^QZX?M1' 2 U>>_O9E$T>S]NW?X6S-DH^:]__!._@J+,H<-PVRT MS3?\Q>3YQ\?'YF.[Z0?W[\SA^/\@GP5_GHW),$OIBC_0Y_O@,*)B/C\A<\/P<)_&I'6=R( MA[OO^(^91YW"1WO\44<^:C.G&-WPPSRFWP=L7 IR[QW\*A]T0K_3,ON+UL>? MD"_ )@I\EZ7$'%OA'3TM?RD 9^3'7A24,0S_$5_K9U^+HZ 4L.$[^%4^& 91 M(WJ>%4&5_%0 %OQ6^$+!H["X>\N:%:X:?RA:-'/_G3S_+]]UV?/4"OY@$>S4 MYLB?XJXWS!:\ +M,T_Z*C/<^)/;^SL8:\>S["5$2AVK(QYM/H?U&_(PK^]N; MT)G.7&# =WP@OF%'OA>QITAS[+^]^13X4WP= 33,R*?/9JLAYTY> K'G1,_B MN^1;Q\;OQPX+-(*/9:@BZ7A^]8\W/QNP3@\G7X@<;P'B:N<[($>O1; >>XT>N6/C[W,)O@4_/GISP MS<\E#_"1_OJN<(*U(#AWK3#\-I9H#NAPXS @IM_G\;_-N;\S%S6':V#-YUN8 M)02*XEG[\5G]10$F3_:7@$FX/T.B#7>6N?K.$OR^GYW5ACV\S,X"9((*&#EW M+OOJ1ZS>2)LQ\P6[BZY R0E(*\XR[3R>CXASVSLX$\Y Y,A]8;9>X-;D5YB& MA1^OX:QGH#S;-Y$_^D/E:$2_$Y&^;KE7@/6P/B VYNN;" B.\(N3@K">@Z&< M, <]+A;PP[[V'S=[HI]39D_X1?RRI:UDX$8U3;X1.$'.L@0)CWPGE/,A$7O1 MF@] ;4&/;5,[-5':J8E24_[@E,_;7NV5;:\,NVQ90S10]!@MR2Z@BPZ/TJ+% M1:R(55SK_K#*-^%U'(PF5LC.[@-&C'OD&_#:M;ROUI0I>ZYLB8?:;Q7AC/0P MKKGA8.>N2M@M:UG28*D)>RKJ<[G/=QF[\UA)O5NC;E="OB(.[43(UVQ2"3;) M2/\,Q;=N8\/HACC6*>SM/+ OS'9&EOLKL]QH1:^< P=F\7QW.F\;0D5^"S;WF) M.^ X^046^?Z[Y=T+3P?^F5GSOM,""E"Z?^59LL N;:>:P5XQ@^W6.,]*,.OI M]3&8NN97R6#[E& U@[U"!MN5!.-Z.D^,YWIZ(LU.D+6.A.RJOBY)LX*^GA=& M>[#I:EZI J]4R+;;3*YD[E_4?+2U?-KX+G1LQPJ>;RR7S6>S%2.\EGK;XN3; M1[_FX?U<&DI0_AUAQ;<^S!K->:^6KF.TSBS!K,E]PZK9EOU\RW] 7? MXV&^S4SEFA%?"2-6U'@72N- Y5B!HB-/#5J2$0Z61BAQOH] U7PD]-@ESCYC MGU45*56)JM>\=$J\=(#P4\U7)\M7%?65+5#::V9\%Z^1KL3[/,X_-T-+>70EDU?YTR?QW?J2MO"EQ.9Z[_S!C%J[_-CO]N M"5_#E6>S)V;?^E=A&+,@O/PS!O#YO[.W!TH1\,H/22'0>@VC+P4:?!XVVD;- M.Y7D'4FJ5>2.H.B.%"P8O=LPQ6U(PM&5-\+%/3 L2H%/'#>_%)366+3, V@[ M@@3[CL&K^)<*_=$J.GPQ\:'FZ;WOU[2US;:J[+1*L241;DT-2.> M,B,>)C^KD*>X7E#SU+9X:@Z?I\-3:QV>-7^="'\=Q^$I'5.GX(OZY'B6-W*P MPGTVOR_KK#I-,5,81ZFI6TOD M0HK[3/\Z[K#E42@:-;Y&JGB7U%JFW2+6V2 5/$1:,G)#1X5_OD3WND3F\UYND MNN=(O4GJ35*M37*P]DBUX;[;@&!MN!_O:5)OE'JC'.U&J=R)\KK4KNILDUKM M.J+3I-XD]2:IVB:IG)>K/&/B%#9%=0SV]3-3CEM2UTQ8,^%Q2,)"$ZCFOX-; MF:] _M6L]UI8KW)2;SXB7?/=82/^KT#>U4QW^DQW##[34^"ZH_;['+>LJ]FN M9KOJZG4GR795.F,KP'85U.QJMCM]MJN<;G?:#N3JG+55TYXZY,5A5>G$=WDE3 M4^Y(]MQI)"6?1'[NGO9J3?'*4/P 735JZA^8^L=7#+MFF0JQ3(5J^ZY5/_W< M]QY8$#EW+OOJ1RR\MIXM^'R*T9=?76%#6C MOA)&/8Y#N-P5?O*,NBL7^+$QZA%)U)I17S.C5DZB+GGTDZ%S#6\X8>@'SX3, MT^'./9_W9#(5(K-FR>5EYVFSY)X%9LV2:_H+3X(!:^98CSF* D8U0YQ&:&B) M]MLGI;77&O4N?10URU2(92KD+2AI]ERSR8'89.\I!S7%*T/Q':<5]50M\8M% M6M/MHZ]:L^HL#43UDR8P:JJ2?=6UZ1[ M._6Z#!I&1W(N?6X;&<[]YK%7SKD)!EXWYPI&685S!3_M2*$ODK,UM[Y>;MW] M82\8KQ:3->.5,%Y.XFV?\?JUQ*L9KYCQ^H]'?'N0!-5W(N_]SA//J)W06QQ4/"KY5WYW'PNKE7,,LJW"MX:A_& M>JY>'QT55V M,5LUNU2(78@Z*[.+V=H-NV!2X#!-VX3/,HI2L\OAV4529P5VD43G?"[88*YJA>;89>M!WM0*'=1:1,789;"Z%3K8J=.BUS &J8?6 MP,D.P V;>PX'*WL.::W[BE=+F7T3L6DXX]K!9Q[GNA[SHV;KY+ M!-AAH;+IYA=Y5''@G8GF4JXHE%)7WDA$1N2=O6N Q8M"-5YR,V*>!> D-TI. MD)T68V>;,9-/CN=$[#/,95]YH,/=XU7!LS!D4?CQ^8OU+S\X=ZTPS-XJS%!E M&] @2FXB&!61*0FL;J\\S>O=5;:[%NR<%_9<9GY:6&0BPRCU%GFEI266*&!3,TH=+B^M2%$SQXD%-Y:AL[A_$+N1,_/Q M^[.IY_B1,_K$(LM%0_*NY7VUIFJIM37I M<3JLN^I95K-QS<:GE+M2<^THYMW*'_>:QHIIS*QT4VKX2D ^U;#WA;XN!S)HY7P5S5CIXB*J' MJM::>-6IYNB:HU=0=U?.LA5\=C@/0Q,E9;@QWY M%ZARE-F3E]@ N..\Q(:+6$4!$VO=F=>FI/S5[U806$>?JDF*T[>Q6,RWX+MS M/XD4899=9:V3+V2);S.\>'OD''$&8]J.&Z,>>\-&<4!*[N73R(UM9B,*SOWI M+(XL7.NW\:45>(YW'UZSX&9B!>SC<_$ "D]ET/3*6:I(*:XERREKP35U7YW: M6U2\K&:#4RM0=@*=YR\ $0_DP;H"1 4Q#O3="?]0*'K0MO.'DMDU:6N!7?/ MJ4AK&3_YSB++\9@M39CC)FYRG?_RSQ@@1B/-]S "D@V+%"_Z=$1Y":W/;-M! MJ]-RKRW'OO+.K9D36>ZK(/G"M9\\Y0$K4]^[B?S1'Z^"VG/K/5D*\QQZ&(6% M9]S_%*ZJU+\$LM1IP8#7@>%FG MUB-J%EGD(ZH5D<,I(A5EF9P;J=98*N!WV*V/:8[6M<)1&;_#GBE?ZPNG2N'Z MN*^,WV%7%%_B/E%]BA_4[U"A'*XEF*56 RKD=S@NUJGUB)I%%B4=UXI(-?P. M%6(9H:\.:HWET!J+HJD.=FJ;Y&E=*QS5\3OLE_*UOG"J%*Z/^^KX'?9"\:.X MOKE[I)1KP$>!H&HKB7-E8BAX8IL\(X8#\[H=]IF?WW M\(0<2/ZD#HXC%8[,740E@PO10H^L-3I =5TX@^T\ -;S6,3WOL93%EB1/U=W M0RB'H,'+X(ZL,7RC7C%ZC;1S;%A9@;[:%;>:\OZ39O[-[)XRPQ@=60=3$ M4]_9>%'"_)N?S[]?GMU>_?-2^W)Y<75^]EF[O3S_]>NWS]]^^1_MUV^?+ZZ^ M_G*C:U=?SYM_?5_L&>EX9%Q7CI:.ED%_Z(+L[?/L^6 M7Z]I-/[!1U=?3P<]@Z]L_/J3:]TO/>K8/[DN"P( MEQ[_JZ]B)#=*.LEY#)H=S.R$(\O]'V8%E]Q%N?0\#7G6+AHMOZC?F>O^P_,? MO1O8O[['[*LPC&&#K;>XDM'RD]Y,+=?]&(>.Q\+E\1@%,5,GRXPR-\4$0,$0 MB.4MS\,*)\R/DI_A$LZ,>\>[_R7P'Z/)JE/E%U,XVMS>Y$3]SF9^$,'#:"_$ MRR/P?_!L>FFT^2UZ36)L56Y4E;_2T?(+I#UQ#C_<^\'RN/SJ>PUK!(<2'N+, MUF@4=:698><7R#<)!^P3?+<\1C_]3W9Q3K)Y#Y9KO7Z?;[_>RYLF"Z/&C7\1W8Q9]R&>>%ULNWUEKB(2B80J.SH0D*TZDD+=LK#P.41\,K!$6O8%]:PG1 ML:[D*1Z-SYDD)%CAY,RS\3\8SWZP7 IE1^=6$#P#E?]IN3$KIB>?=!$]AP,# M[:^5YMH.>(EW8Q%X@T&O,]@(O+/1R N'/95Q8546T%I!DI1(N& MWPB0I=#3[1GKP4*]#C;$0HYU,F.N-MU2:QUV6BHK+)AN07L'0,BZR^V9PWZO MG0*P>)8-(5H*(YUVK]OMK@<1_WI=7/1-.(:Z>6(L.<-RG-TV!D;[A1D$OU]; MS\CL&[)SNVL,AL/YW90=?4T(EEISNV7T!]V5(8##TO[L6'>.2X61-T2#V1WV M^V8&B.()UH=C*628+:,S;*T,QQ?+L^XI^]\# @$'!CV7WMK,O^H-!WU 88O$L&T*T'&L8O5:KUUL/I(N8 MW?K?F8OVT;45;&/'@*123N'R"38 9$F\K =(4L5Q>U*D/>AWS$%;8=]%LVP$ MSU*HZ0TZ_4&_OPXXVT-*Q^CF)/Q6YEY.D>X9K;;16FOJG:QWE=DV7F%>*DVG M3C0ETP&,"9@.3 ?FC398JJ$*H]+1-P%C*1RL T8VE+Z1,:E,7S#J.M.NNNH7 MIU7<)1LMM=\;=-N]++K5<5>>=3F= $R@X;*3EEQ;67?%+;-M=GM#U=XLGF!= M*)8[X_J@E1GF8$4H\K>V0)N,IS$=C1=LC+DBZZ*ET3,'0Y \"B^\/-D6@%L* M6XU6M]OK&L8&P!%W37S79D'(KU.LC:GV$$PZPU0X:'[P-29?#A,#HV]V5/ON MI;F5XP,$Z/;0D+>=7YIG8ZC6LK=7@VJU,V11OMI"I=(P=G?"[ FH"W87I<72 M?_.L*8:<_@V;SPG)VM]8QQSV.D-5SUUNOJU!N:S?,N-K60]*Y?C[ZH.%L]J! M?CT?9FF#+M$TLL9NP13K05&,F!U P4<\BZ.)'R .E\/(/!QH-AGR?X7 Y&?: M!*0"].P!)(K*;X(AU ,[1L_L+X"&3[(N),LB!G3#8=OH%.ND*P#R0KAR!;RT M>XOQ,A>I7!.F%3 $JMI"#)6"E!7L2XF;1=8RMWOV ^8* FLY M8(LY,B\U%@.Q(<"K87<_ +\H[#8 ]@4PBR3/2B!N 9]; G$Y^;@[.)<44:L( MSH,#NYP\77S9M$HBM0J0KB)5EX6WD 7:AQ&LU8+Y9=FZ>WBW)V2K ^N2TG;W M .]"[!X0ZN_L@7DQ6SKK>L; 4Q^(9NTO,>.Z'T;>Q^&T; M"^T:W6'&>E#&7VWJE5?%7F7=U M$K>,S!%8.N\-"RSWS+//[*GCT;T.#.]>/LV8%VZ%_*;9,X<=Q:)= M;NHM@;L&!EOMECG<#-PS[HD3S=GS:67;P&JOU\_D^2R<<$/@5L9AJS?L&NL! M]VV&2?B ;X'7[8C:5FO0;RLTG9ME=2#68*RN8?;6 .+*&_E3]ME?_JK+PI". M:9J=0;M; $ MT6FM#62:Q80OXGO?O/2[?&KQNONLC8';@:%LM!?GW1S,U7'9-8;FL+T^E%]] MS\]NVRUNSD:[VS*-]E !KW2^]<%:'6G]=K?=-5:'*I5K.#-/+XKA%2'X?"_\ MR,9^P/ASM]83"X&= \L/P!:Q@N>KB$U#F O7$/BDETAIL1UT]]JM;JN=D88[ M@_B0J%F=Y ,X-'O]]L$P P,(EOH(FNB6S)0Y0L_-LBXH*R-X55! $&U9,9IG M_LP8-_>LZ\QNI&^C>E%Q1&T,8J+@ZN#8;]M MM/N*JV ]>':TIA<(4K@F.+ [;;/7VNZ2)"&9C9?;02R0C-V*!= WVBV%QXMG M6A.:3>3@,H!D;6O4=67RSW7 IDX\W0:&AOWAL%=JT!=,NCF,JYM1_5:[TS57 M!I)JT9Q/+.\>3NI/EL-#1/B"5'G#LC3[-;&9&@:KS;TE>%?&;&(AK TN-R+R MAEG)_:,MZ36K3[Q%@-?PF'&+=B.H+Y]&+ SAN="QA0[* T97'GSIL1%^\[L3 M3;XSUV$/0+G,[3A,6;VV(OA#4G'I$AK+T&+[T.U[Z:O+)!%KVNGZ%:TY8'!8 M7##^WRMO_F;[5L(YF=OSR\RZ%3A7C_T8NX)SBX*J;9AF9QDH"Z^NK@/B.FY: MH[ME&'-WDK<33NT;K>$+8.;FW0JDZSA\6]W>=B$5J ]O_?,XC,!F7+Z^V,(] M-#0,5:=::N+MP+H&G[:,%[;\B\!BY0\KG%P'/A91M#\^_Q:B?$[B$F=8-8:MDEVP1KM4UT[;1ZJO!UJ4!*SF9/CF> MY8VV?I+WANT,_I:??8M0KXS=X1"O=VT.=7$Y/UY6,Z_S;L7[V^XIYM\JLV\5 M[M7UU);9[1@OUD%<'_0EJC4.EO(!= S5"EBC7*,,'*-HVU+^2B]G2V4F6'7V M-6QD4ZT[],+T28!]B^LOBD)JJ]#M<=5KV"2#G:XZDVRQX)+?\NV_5[V!5GZU;UF8Q/,%3>=?+ MB M#@RUK-("6)8JFK0.EEZJ#K2=KX*I(&U:+I^T&HI*#:@GHP&[O]WO]G4.8 MKX*V!&@-LV\,S':[O2/87JJ=-NSTVOT5Y^;L?Q$'L$9N'7+.I1^_S2BW]_*) M!2,G7#II;BVY\10Z[SW'_=L;;.WP1GNW+UC7EB?=MMGJY-&]$HA++9$LX+U1 M8W&.WJH0[FF!ZXFY;ML\GJ6M+R\;1[7.-:1N]1GTL.#SG:XJBXHY>,/ Z%_% MZ[MOV;XUN->6\]BIKVUTEY7T+P*\/,\=A&9KR4 4/_Y%;Z!C=P;# MCEHH_5A1L+OCI(*K7DS2KF&V,M;OSAT#I&/TX'_+ MGA\$T_+,LS/TKKTS=KF ]>0Y$.!E[.\-]O7%6@[)MD-?;DP<%=8,MB/WTU$X.^P=^LUVW-WAW@\9U MKJ)O;U-M^8[\YEMG5P"MOT'V -PZGOE5"@ZL5&>X(M&QC974^VVS[Y3HL[0:D#6SWN?9'NX%PG5TXWVMHHQA5F=I7E&U0%=.R$+;U8]J= MMMD9#%ZV";9J6VZ,WT/;!6L3H2!8#A18TJNR#^#7EQO#;B9A^] +J;QMN79* MTW9A7#]*4@4IN36XUY>@ [/?-C-5]ZH4_TW]XH<7?[_CK;YT=^+V.'FWPTN+AR\ MWNC9X485_+88!5@,STZ WSP><$"@-_&[9"LK'G(5&X8(]@_Y#C&[2AQCQYMQ M%Z&7'6W!O8.Z04BN/^RV.P<%OH(AN95WV=IH7&@N8_^A(.39JSE5X-MYXM:3S":U5[,!G<#*KZR M]>1J!5>T,Y"7#:CO5K/9(-*_&_UE5P =.B]BV[MEM3X0*_6(KD9BQ.:G=$&; M^@TS([:T_W:0&;'A!N2HVC5,&U@*9MOL]H8[Q]HZ&[%G#H9&:Q7L?0ON+4_4 M_#_WO=!W'9O^P-82 !AP5,B\B'\5AP!0&%ZP7_>W-[>5_WS;./E_]\O6]A@XV9_S\0?OT M[>OM>\TT9I%V>_7E\D;[>OF[]OW;E[.O;_[K/OJ 0\SD /ALX^;J_UWR%_C+ MC4]G7ZX^_\][+7*F+-0\]J@!2);W0?MR]OV7*YC+F#VE_SCP P+?L%SGWGLO MX4@F"Z/ ]^[E7VR*GU1LXK?O^-?T,7U>:VCG >,VUQ=F.R/+U6[9:.+YKG^/ MKOQ?@5Y(-'!>L^S8C6 &-M5 ^+A:A(LA)VA3NP50!7S:HQ5J#IP"P
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

211 E Osborn Road, Phoenix, AZ		85012
(Address of principal executive offices)		(Zip Code)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

	o	La Quinta
	o	Los Angeles
	o	Oakland
	o	San Francisco
	o	Tarzana

	•	We were required to pay CMH $100,000 within 30 days of demand as an initial payment.
	•	In the event we determine to pursue the technology via use of autologous cells, we will pay CMH:

	•	Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.
	•	In the event our shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.
	•	For a period of five years from the date of the first sale of any product derived from the patent, we are required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

	·	failure to secure adequate funding to maintain operations;
	·	international, national and local general economic and market conditions;
	·	our ability to successfully introduce our products to market;
	·	our ability to sustain, manage, or forecast growth;
	·	our ability to successfully make acquisitions of new technologies; new product development and introduction;
	·	existing government regulations and changes in, or the failure to comply with, government regulations;
	·	adverse publicity;
	·	competition; the failure to secure and maintain significant customers or suppliers;
	·	fluctuations and difficulty in forecasting operating results;
	·	changes in business strategy or development plans;
	·	results of testing and clinical trials of our products; business disruptions;
	·	the ability to attract and retain qualified personnel;
	·	the ability to protect technology; and
	·	other risks that might be detailed from time to time.

	·	Preventing the rejection of transplanted organs
	·	Kidney failure
	·	Type 1 Diabetes
	·	Heart attack

	·	A robust web site for each of these products (CaverStem.com and FemCelz.com) designed to attract and educate both physicians and patients
	·	Online advertising
	·	Social Media – Twitter, Facebook
	·	In-office flyers and banners
	·	Patient testimonials
	·	Informative videos

	·	Arizona – Scottsdale
	·	Arkansas – Martinsburg
	·	California

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,00 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

Title	Application Number	Application Filing Date	Patent Number
Methods of Treating Erectile Dysfunction	15590668	05/09/2017
Generation of Autologous Immune Mcratiodulatory Cells for Treatment of Neurological Conditions	15/987,739	05/23/2018
Treatment of Glioma by Amniotic Fluid Stem Cells and Exosomes Derived Thereof	16044256	07/24/2018
Enhancement of Nucleus Pulposus Regeneration by Enhanced Perfusion of Perispinal Area by Combination Drug, Gene and Cellular Therapies	15996182	06/01/2018
Methods For Treatment Of Premature Ovarian Failure And Ovarian Aging Using Regenerative Cells			10,792,310
Inducing and Accelerating Post-Stroke Recovery by Administration of Amniotic Fluid Derived Stem Cells	15702735	09/12/2017
Perispinal Perfusion by Administration of T regulatory Cells Alone or in Combination with Angiogenic Cell Therapies	16009982	06/15/2018	10842815
Improvement of Perispinal Perfusion by Administration of T regulatory Cells Alone or in Combination with Angiogenic Cell Therapies	62520773	06/16/2017
Extracorporeal Shock Wave Ultrasound for Enhancement of Regenerative Activities in Erectile Dysfunction	62809288	02/22/2019
Treatment of Erectile Dysfunction by Stem Cell Therapy			8372797
2020 Patent Applications
Extracorporeal Shock Wave Ultrasound For Enhancement Of Regenerative Activities In Erectile Dysfunction	16799656	02/24/2020
Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells	63123380	12/09/2020
Treatment of Liver Failure by Ex Vivo Reprogrammed Immune Cells	63131261	12/28/2020
Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells	63132472	12/30/2020

	Quarter	High		Low
FISCAL YEAR ENDED DECEMBER 31, 2020	First	$	0.1049	$	0.0038
	Second	$	0.0214	$	0.0020
	Third	$	0.0089	$	0.0025
	Fourth	$	0.0485	$	0.0013

⁽¹⁾	Represents options to purchase 3,333 shares issued under the 2016 Stock Incentive Plan (the “ Plan ”).
⁽²⁾	Represents outstanding options and shares available for future issuance under the Plan and gives effect to 1,667 shares of restricted stock granted to Boris Reznik under the Plan pursuant to a Consulting Agreement.

	1.	an exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002;
	2.	an exemption from the adoption of new or revised financial accounting standards until they would apply to private companies;
	3.	an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about our audit and our financial statements; and
	4.	reduced disclosure about our executive compensation arrangements.

	December 31, 2020			December 31, 2019
ASSETS
CURRENT ASSETS
Cash	$	98,012		$	88,648
Accounts receivable		-			5,600
Total Current Assets		98,012			94,248

OTHER ASSETS
Licenses, net of amortization		619,763			436,555
TOTAL ASSETS	$	717,775		$	530,803

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable	$	350,899		$	320,785
Accrued expenses		159,771			120,492
Management fee and patent liabilities - related parties		468,782			240,082
Convertible notes payable, net of discount of $409,649 and $560,899, respectively		788,701			1,062,266
Advances from related party		10,800			10,800
Derivative liabilities		38,741,832			6,847,877
Total Current Liabilities		40,520,785			8,602,302

TOTAL LIABILITIES		40,520,785			8,602,302

Commitments and contingencies

STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value, 7,000,000 and 7,000,000 shares authorized, no shares issued and outstanding at December 31, 2020 and 2019		-			-
Series A preferred stock, $0.001 par value, 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at December 31, 2020 and 2019		3,000			3,000
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 768,540,617 and 22,493,046 issued and 768,536,617 and 22,489,046 outstanding at December 31, 2020 and 2019, respectively		768,536			22,489
Additional paid-in capital		21,315,690			17,468,018
Accumulated deficit		(61,890,236	)		(25,565,006	)
TOTAL STOCKHOLDERS' DEFICIT		(39,803,010	)		(8,071,499	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	717,775		$	530,803

	·	Florida – Orlando
	·	Hawaii – Honolulu
	·	Texas

	o	Austin
	o	San Antonio
	o	Webster

	·	West Virginia - Fayetteville
	·	Italy

	For the Year Ended December 31, 2020			For the Year Ended December 31, 2019

Revenues	$	164,500		$	165,500

Cost of revenues		50,596			45,499

Gross profit		113,904			120,001

OPERATING EXPENSES
Selling, general and administrative		1,161,947			1,223,219
Amortization of patent costs		66,792			26,950
TOTAL EXPENSES		1,228,739			1,250,169

Operating loss		(1,114,835	)		(1,130,168	)

OTHER INCOME/(EXPENSE)
Interest expense		(1,229,590	)		(1,895,528	)
Gain loss on extinguishment of convertible notes		-			(366,042	)
Change in fair value of derivatives liabilities		(33,980,805	)		(5,091,935	)
Total other income (expense)		(35,210,395	)		(7,353,505	)

LOSS BEFORE PROVISION FOR INCOME TAXES		(36,325,230	)		(8,483,673	)

Provision for income taxes		-			-

NET LOSS	$	(36,325,230	)	$	(8,483,673	)

BASIC AND DILUTED NET LOSS PER SHARE	$	(0.13	)	$	(0.82	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		289,730,374			10,343,162

	Series A Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
December 31, 2018		3,000,000	$	3,000		6,018,075	$	6,018	$	13,077,678		$	(17,081,333	)	$	(3,994,637	)

Common stock issued for cashless warrant exercise		-		-		531,247		531		(531	)		-			-

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		11,873,057		11,873		1,489,402			-			1,501,275

Common stock issued for related party management fee and patent liabilities		-		-		4,066,667		4,067		245,933			-			250,000

Relief of derivative liabilities		-		-		-		-		2,655,536			-			2,655,536

Net loss		-		-		-		-		-			(8,483,673	)		(8,483,673	)

December 31, 2019		3,000,000		3,000		22,489,046		22,489		17,468,018			(25,565,006	)		(8,071,499	)

Common stock issued for related party management fee and patent liabilities		-		-		64,314,883		64,315		95,685			-			160,000

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		681,731,395		681,731		684,974			-			1,366,705

Beneficial conversion feature issued with Allogenics patent liability		-		-		-		-		101,351			-			101,351

Stock-based compensation		-		-		-		-		170,323			-			170,323

Relief of derivative liabilities		-		-		-		-		2,795,340			-			2,795,340

Differences in shares from reverse stock split		-		-		1,293		1		(1	)		-			-

Net loss		-		-		-		-		-			(36,325,230	)		(36,325,230	)

December 31, 2020		3,000,000	$	3,000		768,536,617	$	768,536	$	21,315,690		$	(61,890,236	)	$	(39,803,010	)

Name	Position	Age
*Executive Officers*:
Timothy Warbington	President and Chief Executive Officer	59
Donald Dickerson	Chief Financial Officer & Senior Vice-President	56
*Directors*:
Timothy Warbington	Director	59
Thomas Ichim, PhD	Director	44
Amit Patel, MD	Director	48
Donald Dickerson	Director	56

	·	honest and ethical conduct;
	·	full, fair, accurate, timely, and understandable disclosure in reports and documents that a registrant files with, or submits to, the SEC and in other public communications made by the Company;
	·	avoidance and ethical handling of actual or apparent conflicts of interest, including disclosure to an appropriate person of any material transaction or relationship that reasonably could be expected to give rise to such a conflict;
	·	confidentiality of corporate information;
	·	protection and proper use of corporate assets and opportunities;
	·	compliance with applicable governmental laws, rules, and regulations;
	·	prompt internal reporting of any violations of this Code to an appropriate person; and
	·	accountability for adherence to the Code.

Name		Position		Monthly Reimbursement
Timothy Warbington		Chief Executive Officer, Director		$	20,000

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership ⁽¹⁾			Percent of Class ⁽¹⁾
Named Executive Officers and Directors
Timothy Warbington		119,706,421	⁽²⁾⁽⁷⁾		10.50	%
Donald Dickerson		10,008,623			0.87	%
Thomas Ichim PhD		10,017,245	⁽³⁾		0.87	%
Amit Patel, MD		92,262,709	⁽⁴⁾		7.51	%
Executive Officers and Directors as a Group (4 Persons)		231,994,998			16.95	%
5% Beneficial Holders
Creative Medical Health, Inc. (5) 2008 W Lupine Ave Phoenix, AZ 85029		119,663,309			9.53	%

	The following financial statements are filed with this report:

	Report of Independent Registered Public Accounting Firm.

	Consolidated Balance Sheets at December 31, 2020 and 2019.

	Consolidated Statements of Operations for the years ended December 31, 2020 and 2019.

	Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2020 and 2019.

	Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019.

	Notes to Consolidated Financial Statements.

	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Date: March 17, 2021	By:	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: March 17, 2021	By:	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial and Accounting Officer)

NAME	TITLE	DATE

/s/ Timothy Warbington	Director & Chairman	March 17, 2021
Timothy Warbington

/s/ Donald Dickerson	Director	March 17, 2021
Donald Dickerson

/s/ Thomas Ichim, PhD	Director	March 17, 2021
Thomas Ichim, PhD

/s/ Amit Patel, MD	Director	March 17, 2021
Amit Patel, MD

	1.	Raise your concerns with your supervisor or manager;
	2.	Raise your concerns with the Company’s Chief Executive Officer and/or
	3.	Company legal counsel.

	·	accepting outside employment with, or accepting personal payments from, any organization which does business with the Company or is a competitor of the Company;
	·	accepting or giving gifts of more than modest value to or from vendors or clients of the Company;
	·	competing with the Company for the purchase or sale of property, services or other interests or taking personal advantage of an opportunity in which the Company has an interest;
	·	personally having immediate family members who have a financial interest in a firm which does business with the Company; and
	·	having an interest in a transaction involving the Company or a customer, business partner or supplier (not including routine investments in publicly traded companies).

Name	Ownership	State of Incorporation
StemSpine Inc.	100.00%	Nevada
ImmCelz Inc.	100.00%	Nevada
Creative Medical Technologies Inc.	100.00%	Nevada
AmnioStem LLC	100.00%	Nevada